ST6GAL1 has been reported as a mediator of therapy resistance in other cancer types [72,73,78,79,80,81], but a link between ST6GAL1 and resistance to therapy has not yet been investigated for prostate cancer. This evidence concerns the gene ST6GAL1 and prostate carcinoma.